Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Osteoporosis"
DOI: 10.1007/s11657-019-0637-7
Abstract: SummaryFor the first time ever, the details of osteoporotic treatment were unveiled through the big data published by the government of Japan. The number of patients being treated is low and treatment start is late,… read more here.
Keywords: treatment; national database; bisphosphonates denosumab; osteoporosis treatment ... See more keywords
Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study
Sign Up to like & getrecommendations! Published in 2021 at "Bone Reports"
DOI: 10.1016/j.bonr.2021.101090
Abstract: Purpose Denosumab reduces bone resorption and improves bone mineral density (BMD). Studies have analyzed subsequent treatment transitioning from bisphosphonates to denosumab based on dual-energy X-ray absorptiometry scanning (DXA). Quantitative computed tomography (QCT) can help assess… read more here.
Keywords: subsequent treatment; treatment; prior bisphosphonate; group ... See more keywords
Incidence of osteonecrosis of the jaw (ONJ) in cancer patients with bone metastases treated with bisphosphonates and/or denosumab: some comments and questions
Sign Up to like & getrecommendations! Published in 2018 at "Acta Clinica Belgica"
DOI: 10.1080/17843286.2017.1389473
Abstract: We read with great interest the paper by Loyson et al. reporting the ONJ (osteonecrosis of jaw) incidence in cancer patients receiving bone metastases long-term treatment with bone resorption inhibitors (BRIs): bisphosphonates and/or denosumab [1].… read more here.
Keywords: cancer patients; bone metastases; bisphosphonates denosumab; osteonecrosis jaw ... See more keywords